Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma (GlobeNewswire) - Mar 7, 2025 - P1/2 | N=55 | ReSPECT (NCT01906385) | Sponsor: Plus Therapeutics | "Key highlights from the publication: Twenty-one patients were treated with doses up to 22.3 mCi of Rhenium (186Re) Obisbemeda; No dose-limiting toxicity was observed, and most adverse events were unrelated to the study treatment; Median overall survival (OS) was 11 months, surpassing the standard of care for recurrent glioblastoma, which is approximately 8 months; Median OS was strongly correlated with radiation absorbed dose to the tumor and the percentage of tumor treated; Patients receiving >100 Gy (n=12) had a median OS of 17 months, compared to 6 months for those receiving <100 Gy (n=9) (p=0.001); Absorbed radiation doses to the tumor were as high as 739.5 Gy and were delivered without significant toxicity, exceeding levels achievable with external beam radiation therapy."
P1/2 data • Glioma
|